

ATTACHMENT 101

Page 1

1
2 UNITED STATES DISTRICT COURT
3 FOR THE NORTHERN DISTRICT OF CALIFORNIA
4 Case No. 3:21-cv-03825-VC
5 -----x
6 IN RE: DA VINCI SURGICAL ROBOT LITIGATION,
7 -----
8 THIS DOCUMENT RELATES TO:
9 ALL CASES
10 -----x

11 November 1, 2022

12 12:45 p.m.

13 HIGHLY CONFIDENTIAL

14 Videotaped deposition of IMRON
15 ZAFAR, pursuant to subpoena, before Jineen
16 Pavesi, a Registered Professional
17 Reporter, Registered Merit Reporter,
18 Certified Realtime Reporter and Notary
19 Public of the State of New York, via Zoom,
20 with all other parties in person at Cohen
21 Milstein, 88 Pine Street, New York, New
22 York.

23
24
25

1
2 APP E A R A N C E S :
3 COHEN MILSTEIN SELLERS & TOLL PLLC
4 88 Pine Street, 14th Floor
5 New York, New York 10005
6 Attorneys for Plaintiffs and Proposed
7 Class
8 BY: CHRISTOPHER BATEMAN, ESQ.
9 cbateman@cohenmilstein.com
10
11 HALEY GUILIANO LLP
12 116 West Hubbard, Unit 20
13 Chicago, Illinois 60654
14 Attorneys for Surgical Instrument
15 Service Company
16 BY: DONNY SAMPORNA, ESQ.
17 donny.sampora@ghlaw.com
18 (via telephone)
19
20 SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
21 One Manhattan West
22 New York, New York 10001
23 Attorneys for Intuitive Surgical,
24 Inc.
25 BY: DOUGLAS DeBAUGH, ESQ.
douglas.debaugh@skadden.com
26
27 DEUTSCHE BANK AG
28 FILIALE NEW YORK LITIGATION & REGULATORY
29 ENFORCEMENT
30 1 Columbus Circle
31 New York, New York
32 Attorneys for Witness
33 BY: SARAH SCHOENBACK, ESQ.
34
35 ALSO PRESENT:
36 ANTON EVANGELISTA, The Video Technician
37
38
39
40

1 ZAFAR

2 this meeting today.

3 Q. Again, without getting into the
4 contents of what you discussed, did you
5 review any documents in preparation for
6 the deposition that refreshed your
7 recollection of events?

8 A. I personally did not review any
9 documents.

10 The only thing I did was I
11 looked at my log of research reports in
12 terms of getting the information to my
13 attorney, but, no, I did not read any
14 documents, no.

15 Q. Who is your current employer?

16 | A. Deutsche Bank.

17 Q. What is Deutsche Bank?

18 A. Deutsche Bank is a global
19 investment bank with businesses across the
20 board in financial services.

21 I work in the equity research
22 division, so I provide institutional
23 investors with investment research on
24 publicly-traded companies and, you know,
25 markets in which these public companies

1 ZAFAR

2 compete.

3 I focus specifically on medical
4 technology, as I mentioned earlier.

5 Q. What was the last part, you
6 focus on --

7 A. Medical technology, medical
8 devices, supplies, equipment.

9 Q. What's your title at Deutsche
10 Bank currently?

11 A. I am an equity research analyst
12 with the corporate title of
13 vice-president.

14 Q. How long have you held that
15 position?

16 A. My current position at Deutsche
17 Bank?

18 | O. Yes.

19 A. You know, I'm going to -- I
20 can give you rough date ranges, but I
21 don't remember exact dates off the top of
22 my head to be honest.

23 But I believe I just
24 celebrated, if I'm not mistaken, my third
25 anniversary at DB.

1 ZAFAR

2 supply chain executives in connection with
3 this report?

4 MR. DeBAUGH: Objection to
5 form.

6 A. Yes.

7 Q. Did you talk to Restore
8 Robotics in connection with this report,
9 in research for the report?

10 A. Yes.

11 Q. Did you talk to Intuitive
12 personnel as part of researching this
13 report?

14 A. What I recall is asking a
15 question about this issue on one of the
16 public conference calls.

17 To the extent I had a
18 one-on-one private conversation with them
19 beyond that, I don't recall to be honest.

20 Q. If you go to page 5 of the
21 report, this is the one titled "FDA and
22 Patient Safety Considerations."

First paragraph says, "Safety concerns unlikely to be an impediment. The key fundamental argument we've heard

ZAFAR

2 paragraph 1, it says, "Our February 3rd
3 downgrade was predicated on our belief
4 that refurbished Da Vinci instruments pose
5 a material and increasing risk to
6 Intuitive's INA segment growth over the
7 next couple of years. Not surprisingly,
8 push-back has centered largely around two
9 points," and there are two points under
10 that.

13 A. The push-back, I don't recall
14 what that specifically refers to, because
15 in this context -- yeah, I don't remember
16 specifically.

17 Q. Do you remember who pushed
18 back?

19 A. That's the question, I don't
20 remember if this was in the context of
21 investors or, you know, companies,
22 doctors, whatever, I don't remember the
23 context of that, to be honest.

24 Q. If you go to paragraph 2 here,
25 it says, "Deeper Dive Into the Threat From

ZAFAR

2 Refurbished Da Vinci Instruments: Over
3 the past few weeks we consulted with five
4 regulatory and legal experts to gain
5 further clarity on both the regulatory/FDA
6 and service contract angles."

7 Who were those five experts
8 that you consulted with?

9 MR. DeBAUGH: Objection.

10 A. I don't recall off the top of
11 my head; again, we talked to so many
12 consultants all the time, literally
13 hundreds since this was published, I
14 literally don't remember.

15 Q. And then if you can go to page
16 8, it is a slide that says "510(k)
17 Premarket Notification Does Not Appear
18 Applicable" at the top.

19 It says, "The immediate
20 feedback to our downgrade note was that
21 Restore Robotics is subject to 510(k)
22 approval requirement and that because the
23 company does not have 510(k) clearance, it
24 is therefore in clear violation of FDA
25 regulations."

ZAFAR

Do you remember who provided that feedback that's referenced here?

A. Not specifically, no.

Q. If you go to page 10, the one that says "Regulatory Oversight of Facilities, ISO Certification is the Standard," at the top.

If you look at the third paragraph, it says, "We were able to review a third-party ISO certification received by Restore Robotics for the servicing of EndoWrist instruments. We confirmed that the issuer of this certification, a Germany-based company called DQS MED, is reputable and credible in the Medtech industry."

Do you recall how you confirmed that DQS MED was reputable and credible?

A. I don't recall for certain, but my recollection is that it was on the website, these types of documentations are generally publicly-available.

But I don't remember with certainty, so I will leave that as my

1 ZAFAR

2 question.

3 Q. Sure.

4 I'm wondering if you've ever
5 evaluated in your personal capacity, or in
6 your capacity as a research analyst at
7 Deutsche Bank, whether a medical device
8 required 510(k) clearance?

9 MS. SCHOENBACH: Objection,
10 legal conclusion.

11 MR. BATEMAN: Same objection,
12 vague.

13 A. I don't remember, because if a
14 product is approved, I already know that
15 it is a 510(k) -- I'm not sure I
16 understand the question.

17 Q. Let's move on.

21 A. I do.

22 Q. When did you first learn about
23 Restore Robotics?

24 A. So in normal course of our jobs
25 we were doing a call with a surgeon about,

ZAFAR

interesting tid bit is not worth violating the law.

I do remember being very cautious ahead of that conversation with him, because on one hand it was a potential golden opportunity to get some insight, but I also didn't want to, you know, get insight that I wasn't supposed to know.

So I remember approaching that discussion enthusiastically but also very cautiously in terms of, you know, not becoming privy to information that I'm not supposed to be privy to.

Q. How many times did you speak with counsel for Restore Robotics?

A. One, that I remember.

Q. When you spoke with counsel for Restore Robotics, do you know whether or not that Restore had filed a lawsuit against Intuitive?

A. Again, I don't know, I don't remember, I don't remember the sequence.

Q. I am going to show you a

1 ZAFAR

2 three, four consultants a week, by
3 consultants I mean surgeons, hospital
4 CEOs.

5 If I said literally hundreds,
6 that might have been a little bit
7 hyperbolic, but suffice it to say it's in
8 the dozens.

9 Q. My clarification question,
10 Mr. Zafar, is whether or not you were
11 talking to consultants about Intuitive
12 Surgical in this third-party repair issue
13 or consultants in the normal course of
14 your job?

15 A. In the normal course of my job,
16 sorry for the...

17 Just to clear up the record, if
18 I said hundreds, that was more a figure of
19 speech; if you want -- it was more in the
20 dozens, not hundreds.

21 Q. Apologies, I don't recall your
22 answer to this earlier.

ZAFAR

A . I don ' t .

3 Q. Turning to the first bullet,
4 which reads, "On the FDA side, while
5 summing knowledge that applicable
6 regulations are somewhat nebulous, the
7 majority of regulatory experts came to the
8 conclusion that Restore Robotics is not in
9 violation of FDA rules as a third-party
10 service provider of refurbished
11 instruments," do you see this?

A. Yes.

13 Q. Do you know what information
14 those experts that you spoke with had
15 about Restore Robotics in coming to this
16 determination?

A. I don't remember specifically.

18 Q. Do you know whether the experts
19 that are referred to in this paragraph had
20 spoken to anyone affiliated with Restore
21 Robotics in coming to their conclusion?

A. I don't know.

23 Q. Do you know whether the experts
24 referred to in this paragraph had observed
25 the process of EndoWrist, quote, repair

1

2 C E R T I F I C A T I O N

3

4

5

6 I, Jineen Pavesi, a Registered
7 Professional Reporter, Registered Merit
8 Reporter, Certified Realtime Reporter and
9 a Notary Public, do hereby certify that
10 the foregoing witness, IMRON ZAFAR, was
11 duly sworn on the date indicated, and that
12 the foregoing is a true and accurate
13 transcription of my stenographic notes.

14 I further certify that I am not employed
15 by nor related to any party to this
16 action.

17

18

19

20

21

22

23

24

25

Jineen Pavesi, RPR, RMR

JINEEN PAVESI, RPR, RMR, CRR